Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus HUMALOG MIX 75 25 PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 75 25 KWIKPEN versus HUMALOG MIX 75 25 PEN.
HUMALOG MIX 75/25 KWIKPEN vs HUMALOG MIX 75/25 PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by promoting peripheral glucose uptake (especially in muscle and adipose tissue) and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling pathways.
Insulin analog with intermediate-acting insulin (insulin lispro protamine suspension) and rapid-acting insulin (insulin lispro). Binds to insulin receptors, activating glucose uptake, glycogen synthesis, and lipogenesis, while inhibiting gluconeogenesis and ketogenesis.
Subcutaneous injection, individualized based on metabolic needs. Typical adult dose: 0.5-1.0 units/kg/day divided into preprandial doses. Administer within 15 minutes before a meal.
Subcutaneous injection. Individualized based on metabolic needs. Typical total daily insulin dose: 0.5-1 unit/kg/day divided, with Humalog Mix 75/25 given 15 minutes before meals. Starting dose: 0.2-0.3 unit/kg/day for type 1 diabetes; 0.3-0.5 unit/kg/day for type 2 diabetes. Administer twice daily: before breakfast and before dinner. Dose adjustments based on blood glucose monitoring.
None Documented
None Documented
4-6 minutes for insulin lispro (rapidly absorbed and cleared); terminal elimination half-life of insulin lispro is approximately 1 hour (reflecting dissociation from insulin receptors). Clinical context: the brief half-life allows for rapid dose adjustments and reduced risk of late hypoglycemia.
Insulin lispro protamine: 13-16 hours (intermediate component); Insulin lispro: 1-2 hours (rapid component). Clinical context: Steady state achieved after 2-4 days of dosing.
Renal: 100% (metabolized to inactive metabolites; metabolites excreted via kidneys). Biliary/fecal: negligible.
Renal: 30-80% (protamine-insulin complex clearance); Hepatic: 10-20% (degradation by insulinase); Fecal: <1%
Category C
Category C
Insulin Analog
Insulin Analog